ARTHQ (Arch Therapeutics) Receivables Turnover: 0.00 (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Receivables Turnover?

Arch Therapeutics ARTHQ -99.00% 12 Receivables Turnover is 0.00 as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Arch Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.03 Mil. Arch Therapeutics's average Accounts Receivable for the three months ended in Jun. 2024 was $0.00 Mil.

Arch Therapeutics  (OTCPK:ARTHQ) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Arch Therapeutics Receivables Turnover Related Terms

Arch Therapeutics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Receivables Turnover Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ARTHQ vs GRTSQ, MTEM, PXMD: Receivables Turnover Comparison

For the Biotechnology subindustry, Arch Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Therapeutics Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Receivables Turnover falls into.


ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Arch Therapeutics's Receivables Turnover for the fiscal year that ended in Sep. 2023 is calculated as

Receivables Turnover (A: Sep. 2023 )
=Revenue / Average Accounts Receivable
=Revenue (A: Sep. 2023 ) / ((Accounts Receivable (A: Sep. 2022 ) + Accounts Receivable (A: Sep. 2023 )) / count )
=0.076 / ((0 + 0) / 1 )
=0.076 / 0
=N/A

Arch Therapeutics's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

Receivables Turnover (Q: Jun. 2024 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2024 ) / ((Accounts Receivable (Q: Mar. 2024 ) + Accounts Receivable (Q: Jun. 2024 )) / count )
=0.031 / ((0 + 0) / 1 )
=0.031 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Arch Therapeutics (ARTHQ) has a Receivables Turnover of 0.00 as of Jun. 2024. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Receivables Turnover too high?
Arch Therapeutics' current Receivables Turnover is 0.00. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Receivables Turnover compare to GRTSQ and MTEM?
Arch Therapeutics' Receivables Turnover of 0.00 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Arch Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arch Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Receivables Turnover is 0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price